Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Cisplatin, and Docetaxel in Advanced NSCLC
NCT01368848Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Apr 2010
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: Objective Response Rate at 4 years. Started Apr 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01368848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01368848.